Want to see TSE:EPRX full AI Analyst Report?
Top Page
Eupraxia Pharmaceuticals
(TSX:EPRX)
Select Model
Select Model
Rating:50Neutral
Price Target:
C$9.50
▼(-6.86% Downside)
Action:Reiterated
Date:10/21/26
The score is primarily held back by weak financial performance typical of a pre-revenue biotech (no revenue, widening losses, and rising cash burn), implying continued reliance on external funding. This is partially offset by a comparatively strong, low-debt balance sheet and a mixed technical picture with longer-term price support but neutral-to-soft momentum. Valuation remains challenging due to negative earnings and no dividend yield data.
Positive Factors
Proprietary delivery platform
A proprietary platform focused on controlled local drug release provides a reusable development foundation across multiple indications. If clinical and regulatory work succeeds, the technology could support differentiated therapies designed to improve outcomes while reducing systemic exposure.
Negative Factors
Pre-revenue business model
With no reported revenue, Eupraxia has not yet established commercial demand or an operating revenue base to fund development. Its financial profile therefore remains dependent on successful clinical progress, regulatory advancement, and eventual product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary delivery platform
A proprietary platform focused on controlled local drug release provides a reusable development foundation across multiple indications. If clinical and regulatory work succeeds, the technology could support differentiated therapies designed to improve outcomes while reducing systemic exposure.
Read all positive factors
Eupraxia Pharmaceuticals (EPRX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$674.18M
Dividend YieldN/A
Average Volume (3M)95.54K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue GrowthN/A
EPS Growth-15.34%
CountryCA
Employees49
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.02
Shares Outstanding65,018,974
10 Day Avg. Volume99,087
30 Day Avg. Volume95,541
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$23.81Price Target Upside133.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.88
Revenue Forecast (FY)N/A
Eupraxia Pharmaceuticals Business Overview & Revenue Model
Company Description
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, tar...
Eupraxia Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -358.86K | -241.88K | -163.47K | -158.05K | -193.27K | -111.53K |
| EBITDA | -55.76M | -38.86M | -23.42M | -28.20M | -22.14M | -21.96M |
| Net Income | -49.89M | -39.25M | -24.28M | -28.15M | -23.26M | -22.99M |
Balance Sheet | ||||||
| Total Assets | 139.68M | 85.99M | 34.94M | 20.12M | 25.88M | 31.22M |
| Cash, Cash Equivalents and Short-Term Investments | 133.44M | 80.42M | 33.10M | 19.34M | 24.74M | 29.90M |
| Total Debt | 1.84M | 154.08K | 71.86K | 10.45M | 10.55M | 9.49M |
| Total Liabilities | 10.22M | 5.69M | 3.10M | 19.23M | 14.51M | 11.67M |
| Stockholders Equity | 131.06M | 81.89M | 33.40M | 2.21M | 12.86M | 20.39M |
Cash Flow | ||||||
| Free Cash Flow | -36.57M | -29.65M | -30.10M | -21.09M | -19.08M | -15.07M |
| Operating Cash Flow | -35.84M | -29.05M | -29.99M | -21.02M | -18.78M | -14.64M |
| Investing Cash Flow | -79.50M | -599.26K | -75.16K | -73.20K | 8.70M | -14.45M |
| Financing Cash Flow | 129.47M | 77.39M | 45.78M | 21.35M | 13.52M | 49.92M |
Eupraxia Pharmaceuticals Technical Analysis
Positive
10.20
Price Trends
10.61
Negative
9.82
Positive
10.18
Positive
Market Momentum
-0.23
Positive
48.79
Neutral
38.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Positive. The current price of 10.2 is below the 20-day moving average (MA) of 10.41, below the 50-day MA of 10.61, and above the 200-day MA of 10.18, indicating a neutral trend. The MACD of -0.23 indicates Positive momentum. The RSI at 48.79 is Neutral, neither overbought nor oversold. The STOCH value of 38.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EPRX.
Eupraxia Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
TSE:EPRX
Eupraxia Pharmaceuticals
10.28
2.68
35.26%
TSE:DRUG
Bright Minds Biosciences
77.76
0.04
0.05%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.11
-1.89
-94.50%
Eupraxia Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects
Positive
Aug 11, 2026
Eupraxia Pharmaceuticals reported a wider second-quarter net loss of $14.5 million, up from $8.7 million a year earlier, as it doubled the size of its RESOLVE Part 2 trial and expanded its organizational footprint to Vancouver and Seattle. Despite...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.